Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA   US04033A1007

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/14/2014 08/15/2014 08/18/2014 08/19/2014 08/20/2014 Date
5.77(c) 5.87(c) 5.94(c) 5.98(c) 6.04 Last
3 568 793 5 519 203 4 840 521 4 489 058 6 066 089 Volume
+1.23% +1.73% +1.19% +0.67% +1.00% Change
More quotes
Company
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113. Its approach to structure-based drug... 
Sector
Pharmaceuticals
Calendar
11/11Earnings Release
Surperformance© rating of Ariad Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More about the company
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 62,0 M
EBIT 2014 -214 M
Net income 2014 -215 M
Finance 2014 92,5 M
Yield 2014 -
Sales 2015 160 M
EBIT 2015 -139 M
Net income 2015 -134 M
Finance 2015 97,7 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 16,6x
EV / Sales 2015 6,38x
Capitalization 1 118 M
More Financials
Latest news on ARIAD PHARMACEUTICALS, INC
6d ago ARIAD PHARMACEUTICALS : Enters into Commercial Pact for Iclusig (Ponatinib) in I..
08/13 ARIAD PHARMACEUTICALS : Reports Second Quarter 2014 Financial Results and Develo..
08/08 ARIAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
08/08 ARIAD PHARMACEUTICALS : Other Events (form 8-K)
08/08 ARIAD PHARMACEUTICALS : Enters into Commercial Agreement for Iclusig (Ponatinib)..
08/06 THE ZACKS ANALYST BLOG HIGHLIGHTS : AbbVie, Shire, ARIAD Pharmaceuticals, Immuno..
08/06 ARIAD PHARMACEUTICALS : Results of Operations and Financial Condition, Regulatio..
08/06 ARIAD PHARMACEUTICALS : Reports Second Quarter 2014 Financial Results and Develo..
08/05 ARIAD PHARMACEUTICALS : Announces Commercial Agreement for Iclusig (Ponatinib) i..
07/23 ARIAD PHARMACEUTICALS : Announces Continuation of Iclusig Review under the Artic..
07/18 ARIAD PHARMACEUTICALS : Assigned Patent
07/17 ARIAD PHARMACEUTICALS : Thursday's ETF Movers: GDXJ, XBI
More news
Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
Ariad Pharmaceuticals, Inc : Income Statement Evolution
More Financials
EPS Revisions
Ariad Pharmaceuticals, Inc : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF